Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 9;59(8):1453-1462.
doi: 10.1515/cclm-2021-0214. Print 2021 Jul 27.

Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers

Christian Irsara  1 , Alexander E Egger  1 , Wolfgang Prokop  1 , Manfred Nairz  2 , Lorin Loacker  1 , Sabina Sahanic  2 , Alex Pizzini  2 , Thomas Sonnweber  2 , Barbara Holzer  3 , Wolfgang Mayer  4 , Harald Schennach  4 , Judith Loeffler-Ragg  2 , Rosa Bellmann-Weiler  2 , Boris Hartmann  3 , Ivan Tancevski  2 , Günter Weiss  2 , Christoph J Binder  5 , Markus Anliker  1 , Andrea Griesmacher  1 , Gregor Hoermann  1   6
Affiliations
Free article

Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers

Christian Irsara et al. Clin Chem Lab Med. .
Free article

Abstract

Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections cause coronavirus disease 2019 (COVID-19) and induce a specific antibody response. Serological assays detecting IgG against the receptor binding domain (RBD) of the spike (S) protein are useful to monitor the immune response after infection or vaccination. The objective of our study was to evaluate the clinical performance of the Siemens SARS-CoV-2 IgG (sCOVG) assay.

Methods: Sensitivity and specificity of the Siemens sCOVG test were evaluated on 178 patients with SARS-CoV-2-infection and 160 pre-pandemic samples in comparison with its predecessor test COV2G. Furthermore, correlation with virus neutralization titers was investigated on 134 samples of convalescent COVID-19 patients.

Results: Specificity of the sCOVG test was 99.4% and sensitivity was 90.5% (COV2G assay 78.7%; p<0.0001). S1-RBD antibody levels showed a good correlation with virus neutralization titers (r=0.843; p<0.0001) and an overall qualitative agreement of 98.5%. Finally, median S1-RBD IgG levels increase with age and were significantly higher in hospitalized COVID-19 patients (median levels general ward: 25.7 U/mL; intensive care: 59.5 U/mL) than in outpatients (3.8 U/mL; p<0.0001).

Conclusions: Performance characteristics of the sCOVG assay have been improved compared to the predecessor test COV2G. Quantitative SARS-CoV-2 S1-RBD IgG levels could be used as a surrogate for virus neutralization capacity. Further harmonization of antibody quantification might assist to monitor the humoral immune response after COVID-19 disease or vaccination.

Keywords: COVID-19; SARS-CoV-2; neutralization assay; sensitivity; serology; specificity.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhu, N, Zhang, D, Wang, W, Li, X, Yang, B, Song, J, et al.. A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. https://doi.org/10.1056/nejmoa2001017.
    1. Guan, WJ, Ni, ZY, Hu, Y, Liang, WH, Ou, CQ, He, JX, et al.. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. https://doi.org/10.1056/nejmoa2002032.
    1. World Health Organization. Virtual press conference on COVID-19 – 11 March 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/transcripts/who-aud... [Accessed 20 Oct 2020].
    1. Forni, G, Mantovani, A. Covid-19 Commission of Accademia Nazionale dei Lincei R. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 2021;28:626–39.
    1. European Medicines Agency (EMA). Section COVID-19 - treatments and vaccines - authorised medicines. Available from: www.ema.europa.eu [Accessed 28 Jan 2021].

MeSH terms

LinkOut - more resources